# A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

Source: https://onco.cc/trials/nct06888921/  
OnCo record `nct06888921` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of COM701 in ovarian cancer, run by Compugen Ltd, now recruiting.

## Summary

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer is a phase 1/2 interventional study registered as NCT06888921 by Compugen Ltd, with 60 participants planned, started 2025-07-21 and due to reach its primary completion in 2027-03. Interventions recorded: COM701 and Normal Saline.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06888921
- Phase: 1/2
- Setting: An Adaptive Clinical Platform Trial to Evaluate the Safety and Efficacy of COM701 as Monotherapy or Combination Therapy as Maintenance Therapy in Participants With Relapsed Platinum Sensitive Ovarian Cancer (PSOC)
- Sponsor: Compugen Ltd
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06888921: https://clinicaltrials.gov/study/NCT06888921

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)

---
JSON: https://onco.cc/api/v1/entities/nct06888921.json